新科学想法 学术文库 学术文献 浏览文献

有附件Aflibercept for age-related macular degeneration: a game-changer or quiet addition?

yucloud 添加于 2012-8-9 11:14 | 980 次阅读 | 0 个评论
  •  作 者

    Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW
  •  摘 要

    PURPOSE: To describe the pharmacokinetics, preclinical studies, and clinical trials of the newly approved anti-vascular endothelial growth factor (VEGF) drug aflibercept (Eylea (VEGF Trap-Eye); Regeneron; and Bayer). DESIGN: Review with editorial commentary. METHODS: A review of the medical literature and pertinent Internet postings combined with analysis of key studies with expert opinion regarding the use of aflibercept for the treatment of exudative age-related macular degeneration. RESULTS: Aflibercept, a fusion protein with binding domains from native VEGF receptors, binds VEGF-A, VEGF-B, and placental growth factors 1 and 2 with high affinity. Preclinical ophthalmologic studies demonstrated that aflibercept suppresses choroidal neovascularization in several animal models. The results of phase 1 and 2 trials showed excellent short-term suppression of choroidal neovascularization in patients with exudative age-related macular degeneration and suggested a longer durability of aflibercept compared with other anti-VEGF drugs. The pivotal phase 3 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration 1 and 2 trials showed that monthly and bimonthly aflibercept were noninferior to monthly ranibizumab at preventing vision loss (< 15-letter loss) with comparable vision gains and safety. Year 2 treatment involved monthly pro re nata injections with required injections every 3 months and maintained vision gains from the first year, with an average of 4.2 injections of aflibercept and 4.7 injections of ranibizumab. CONCLUSIONS: Aflibercept promises to deliver excellent visual outcomes for exudative age-related macular degeneration patients while undergoing fewer injections compared with ranibizumab. With a wholesale cost of $1850 per dose, the cost per patient with aflibercept treatment promises to be lower than with ranibizumab.
  •  详细资料

    • 文献种类: Journal Article
    • 期刊名称: American Journal of Ophthalmology
    • 期刊缩写: Am J Ophthalmol
    • 期卷页: 2012  154 2 222-226
    • 地址: Charlotte Eye, Ear, Nose and Throat Associates, Charlotte, North Carolina
    • ISBN: 0002-9394
  • 学科领域 生物医药 » 药学

  • 相关链接 DOI URL 

  •  yucloud 的文献笔记  订阅

管理选项: 导出文献|

评论(0 人)

facelist doodle 涂鸦板

Copyright;  © 新科学想法 2016-2017   浙公网安备 33010202000686号   ( 浙ICP备09035230号-1 )